Altimmune (ALT) Shares Outstanding (Diluted Average) (2014 - 2026)

Altimmune (ALT) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $124.5 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 64.75% year-over-year to $124.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.5 million (up 64.75% YoY) and the FY2025 annual result came in at $88.1 million, up 24.08% from the prior year.
• Shares Outstanding (Diluted Average) rose to $124.5 million in Q1 2026 per ALT's latest filing, from $88.1 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $124.5 million in Q1 2026 and bottomed at $44.0 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $70.8 million (2024), against an average of $66.0 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) rose 6.12%; it then soared 64.75% in 2026.
• Tracing ALT's Shares Outstanding (Diluted Average) over 5 years: stood at $46.9 million in 2022, then climbed by 13.47% to $53.2 million in 2023, then soared by 33.35% to $71.0 million in 2024, then grew by 24.08% to $88.1 million in 2025, then surged by 41.27% to $124.5 million in 2026.
• Per Business Quant, the three latest ALT Shares Outstanding (Diluted Average) figures stand at $124.5 million (Q1 2026), $88.1 million (Q4 2025), and $82.2 million (Q3 2025).

Peer Comparison